Literature DB >> 25511979

When do we judge IVIg for myasthenia gravis ineffective?

Tsubasa Takizawa1, Shigeaki Suzuki, Norihiro Suzuki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25511979     DOI： 10.1007/s10072-014-2039-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  5 in total

1.  Clinical and immunological differences between early and late-onset myasthenia gravis in Japan.

Authors:  Shigeaki Suzuki; Kimiaki Utsugisawa; Yuriko Nagane; Takashi Satoh; Masataka Kuwana; Norihiro Suzuki
Journal:  J Neuroimmunol       Date:  2010-11-12       Impact factor: 3.478

2.  Comparison of IVIg and PLEX in patients with myasthenia gravis.

Authors:  D Barth; M Nabavi Nouri; E Ng; P Nwe; V Bril
Journal:  Neurology       Date:  2011-05-11       Impact factor: 9.910

3.  Intravenous immunoglobulin for prophylaxis of acute exacerbation in Myasthenia Gravis.

Authors:  Mine Hayriye Sorgun; Huseyin Ozden Sener; Canan Yucesan; Nezih Yucemen
Journal:  Neurol Sci       Date:  2014-01-08       Impact factor: 3.307

4.  Mycophenolate mofetil for myasthenia gravis: an open-label pilot study.

Authors:  E Ciafaloni; J M Massey; B Tucker-Lipscomb; D B Sanders
Journal:  Neurology       Date:  2001-01-09       Impact factor: 9.910

5.  IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial.

Authors:  Lorne Zinman; Eduardo Ng; Vera Bril
Journal:  Neurology       Date:  2007-03-13       Impact factor: 9.910
  5 in total
  1 in total

Review 1.  Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence.

Authors:  Masoud Etemadifar; Mehri Salari; Omid Mirmosayyeb; Mehdi Serati; Roham Nikkhah; Mozhde Askari; Emad Fayyazi
Journal:  J Res Med Sci       Date:  2017-02-16       Impact factor: 1.852
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.